PRINCETON, NJ--(Marketwire - October 28, 2008) - Agile Therapeutics, Inc., a late-stage pharmaceutical company specializing in women's health products, announced today that the United States Patent and Trademark Office (USPTO) has issued two patents for its proprietary transdermal delivery technology. The patents (US 7,045,145 and US 7,384,650) for the Company's SKINFUSION™ technology covers the intermediate formulation during manufacturing and the finished product for a transdermal patch containing estrogen and progestin used in contraception. Agile's lead product, AG200-15, is a new, innovative, low-dose, weekly contraceptive patch entering Phase 3 clinical development. The patch will provide women with a convenient alternative to oral contraceptives by avoiding the need to remember to take a pill every day.
